Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04719156 · ClinicalTrials.gov registry record · Phase 2
Fluorescent Intra-operative Tumor Margin Examination
A Phase 2 study of Sarcoma, sponsored by Kurt Weiss.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT04719156 is a Phase 2 study of Sarcoma that is actively recruiting participants, run by Kurt Weiss. The registered enrollment target is 110 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04719156, a Phase 2 study of Sarcoma, is actively recruiting participants, sponsored by Kurt Weiss.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.
Conditions Studied
Interventions
- DRUG Indocyanine green solution administered at 2.0mg/kg.
- DEVICE Stryker SPY-PHI Imaging Device
Study Locations (1)
Pennsylvania
- UPMC-Shadyside Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04719156
The ClinicalTrials.gov registry entry for NCT04719156 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (88% lower). The listed sponsor is Kurt Weiss, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Indocyanine green solution administered at 2.0mg/kg. is the first listed.
NCT04719156 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04719156 about?
NCT04719156 is a clinical study titled "Fluorescent Intra-operative Tumor Margin Examination". Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In pr...
What is the current status of trial NCT04719156?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2021-03-02. Estimated completion is 2026-12-31.
What conditions does trial NCT04719156 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT04719156?
The interventions under investigation include: Indocyanine green solution administered at 2.0mg/kg. (DRUG), Stryker SPY-PHI Imaging Device (DEVICE).
Who is sponsoring clinical trial NCT04719156?
This trial is sponsored by Kurt Weiss, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04719156 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.